Edition:
India

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

81.20EUR
16 Nov 2018
Change (% chg)

€1.20 (+1.50%)
Prev Close
€80.00
Open
€80.05
Day's High
€81.50
Day's Low
€80.05
Volume
43,768
Avg. Vol
90,186
52-wk High
€99.20
52-wk Low
€65.05

Latest Key Developments (Source: Significant Developments)

Diasorin And Meridian Enter Strategic Pact To Sell Stool Antigen Test In U.S. And UK
Wednesday, 10 Oct 2018 

Oct 9 (Reuters) - Meridian Bioscience Inc ::PRESS RELEASE - DIASORIN AND MERIDIAN ENTER INTO A STRATEGIC COLLABORATION TO SELL HELICOBACTER PYLORI STOOL ANTIGEN TEST IN THE UNITED STATES AND IN THE UNITED KINGDOM.MERIDIAN BIOSCIENCE INC - MERIDIAN AND DIASORIN WILL BEGIN COLLABORATING ON SALES AND MARKETING EFFORTS TO HOSPITALS AND REFERENCE LABORATORIES IN U.S.MERIDIAN BIOSCIENCE - COLLABORATION TO RESULT IN TERMINATION OF PENDING LEGAL DISPUTES AND WILL EXPAND SCOPE OF AGREEMENT BETWEEN DIASORIN AND MERIDIAN.MERIDIAN BIOSCIENCE INC - MERIDIAN WILL RECEIVE ROYALTIES ON SALES OF LIAISON H. PYLORI STOOL ANTIGEN TEST IN U.S. AND NOW ALSO IN UK.MERIDIAN BIOSCIENCE - MERIDIAN AND DIASORIN HAVE OUTLINED A FRAMEWORK WHERE THEY MAY PARTNER TO DEVELOP OTHER STOOL-BASED TESTS FOR USE ON LIAISON PLATFORM.  Full Article

Diasorin And Meridian Enter Into A Strategic Collaboration
Wednesday, 10 Oct 2018 

Oct 9 (Reuters) - Diasorin Spa ::SAYS DIASORIN AND MERIDIAN ENTER INTO A STRATEGIC COLLABORATION TO SELL HELICOBACTER PYLORI STOOL ANTIGEN TEST IN U.S. AND IN U.K.MERIDIAN AND DIASORIN WILL BEGIN COLLABORATING ON SALES AND MARKETING EFFORTS TO HOSPITALS AND REFERENCE LABORATORIES IN U.S..MERIDIAN WILL RECEIVE ROYALTIES ON SALES OF LIAISON H. PYLORI STOOL ANTIGEN TEST IN U.S. AND ALSO IN UK.MERIDIAN AND DIASORIN HAVE OUTLINED A FRAMEWORK WHERE THEY MAY PARTNER TO DEVELOP OTHER STOOL-BASED TESTS FOR USE ON LIAISON PLATFORM.  Full Article

Diasorin Q2 Net Profit Up At EUR 42.5 Mln
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - DiaSorin SpA ::Q2 REVENUE EUR 166.7 MILLION VERSUS EUR 161.8 MILLION YEAR AGO.Q2 NET PROFIT EUR 42.5 MILLION VERSUS EUR 33.6 MILLION YEAR AGO.UPDATES 2018 GUIDANCE.SEES 2018 REVENUE GROWTH EQUAL TO AROUND +9% AT CONSTANT CURRENCIES VERSUS 2017 (PREVIOUS GUIDANCE: AROUND +11%).SEES 2018 EBITDA GROWTH AROUND +12% AT CONSTANT CURRENCIES VERSUS 2017 (PREVIOUS GUIDANCE: AROUND +13%).  Full Article

Diasorin Launches Hepatitis Delta (HDV) Test On Liaison XL Platform
Friday, 27 Jul 2018 

July 27 (Reuters) - DiaSorin SpA ::LAUNCHES THE TEST FOR THE DETECTION OF THE HEPATITIS DELTA (HDV) ON LIAISON XL IN EUROPE.  Full Article

Qiagen, DiaSorin partner in automated tuberculosis detection
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Qiagen Nv ::SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​.SAYS ‍DIASORIN TO ADD NOVEL CONTENT TO ALREADY BROAD LIAISON MENU, OVER 7,000 SYSTEMS INSTALLED​.SAYS ‍ANNOUNCES MILESTONE OF OVER 40 MILLION QUANTIFERON-TB TESTS SINCE LAUNCH​.  Full Article

Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis
Monday, 8 Jan 2018 

Jan 8 (Reuters) - DIASORIN SPA ::ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS.UNDER AGREEMENT, PARTIES ARE DEVELOPING FULLY AUTOMATED VERSION OF QUANTIFERON TEST READ-OUT COMPONENTS.  Full Article

DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - DIASORIN SPA ::Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO.Q3 NET PROFIT EUR 29.3‍​ MILLION VERSUS EUR 28.7 MILLION YEAR AGO.REAFFIRMS ITS FY'17 GUIDANCE‍​.  Full Article

DiaSorin launches test Liaison SHBG to diagnose androgen-related disorders
Tuesday, 23 May 2017 

May 23 (Reuters) - DIASORIN SPA ::LAUNCHES TEST LIAISON SHBG FOR DIAGNOSIS OF DISORDERS RELATED TO THE ANDROGEN HORMONES.SGHB, WHICH IS PRODUCED IN LIVER, IS INVOLVED IN TRANSPORT OF SEX STEROIDS, SUCH AS DIHYDROTESTOSTERONE, TESTOSTERONE AND ESTRADIOL, IN BLOOD STREAM.ACCORDING TO GLOBAL DIAGNOSTIC MARKET STATISTICS, EUROPEAN INFERTILITY MARKET IS ESTIMATED AT 130 MILLION EUROS WITH SHBG ACCOUNTING FOR ABOUT 4%, EQUAL TO A VOLUME EXCEEDING 2.7 MILLION TESTS PER YEAR.  Full Article